Clinical trial NCT04317326: "Post-acute Pickwick Study" (Postacute-Pick-2020)
Official title: "Mid- and Long-term Effectiveness of Positive Airway Pressure in OHS After an Acute-on-chronic Hypercapnic Respiratory Failure"
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Acute on Chronic Hypercapnic Respiratory Failure
Obesity Hypoventilation Syndrome (OHS)
Keywords: Hypercapnic respiratory failure
Obesity
Non invasive mechanical ventilation
CPAP
Lead sponsor: Sociedad Española de Neumología y Cirugía Torácica
Sponsor class: OTHER
Collaborators: name: Rush University Medical Center
First posted: 2020-03-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective, open label, randomized controlled trial with two sequential phases
Primary purpose: TREATMENT

Brief summary: We propose to carry out a large multicentric, multinational, randomized controlled trial with two phases (two sequential randomized controled trials) to answer two questions: 1) Should hospitalized patients with recently diagnosed OHS be discharged from the hospital on an auto-titratable NIV treatment until the diagnosis of OHS is confirmed in 3 months? 2) Is the long-term effectiveness of outpatient titrated CPAP non-inferior to titrated NIV in ambulatory patients with OHS 3 months after hospital discharge? Clinical practice, multicenter open-label controlled randomized clinical trial with preset allocation rate (1:1) with two parallel-groups conducted in centers from Spain, France, Portugal and USA. The study will have two phases with two randomizations. The first phase will be a superiority study and the second phase will be a non-inferiority study.

Detailed description: Objectives: First phase (medium-term): To evaluate the medium-term (3 months) efficacy of automatically adjusted noninvasive ventilation (NIV) treatment versus "life style modifications" treatment in obesity hypoventilation syndrome (OHS) after an episode of acute-on-chronic hypercapnic respiratory failure. The main outcome will be a composite that includes hospital resource utilization (hospital and ICU admissions and emergency department visits for any cause) and all-cause mortality. Key secondary outcomes will include incident cardiovascular events (new hypertension diagnosis or initiation of anti-hypertensive treatment, atrial fibrillation, hospitalization for nonfatal myocardial infarction or unstable angina, percutaneous coronary interventions, nonfatal stroke or transient ischemic attack or for acute heart failure episode, and cardiovascular death), blood pressure, arterial blood gases, clinical symptoms and quality of life. Second phase (long-term): Evaluate the long-term efficacy (36 months) of manually titrated NIV treatment versus manually titrated CPAP treatment in OHS after 3 months of an episode of acute-on-chronic hypercapnic respiratory failure, with a composite outcome of hospital resource utilization (hospital and ICU admissions, emergency department visits) and all-cause mortality analyzed as the primary outcome. Incident cardiovascular events, blood pressure, arterial blood gases, clinical symptoms and quality of life will be the main secondary outcomes.

Methods: Prospective, multinational, randomized open-label controlled trial with two parallel arms: 1,110 hospitalized patients with newly diagnosed OHS with acute-on-chronic hypercapnic respiratory failure treated with invasive or noninvasive mechanical ventilation who survive hospitalization and available for hospital discharge will be randomized to either automatically adjusted NIV (555 patients) or "life style modifications" (555 patients) for three months. Subsequently, both automatically adjusted NIV and "life style modifications" arms will be re-randomized to polysomnographically adjusted CPAP or to polysomnographically adjusted NIV groups to complete 36 months of follow up. The first phase of the proposal is a superiority study and the second phase is a non-inferiority study. The primary outcome and its components will be analyzed by a mixed-effects model with negative binomial. A mixed-effects Cox model will be used for hospital resource utilization, new cardiovascular events and overall survival. Other secondary outcomes such as repeated measures derived from the arterial blood gases (i.e. PaCO2, PaO2, pH, calculated bicarbonate), blood pressure, health-related quality of life tests and Epworth Sleepiness Scale during the follow-up will be analyzed by a linear mixed-effects model.

Eligibility criteria: Inclusion Criteria:

1. º.- Patient between 18 and 85 years old.
2. º.- With diagnosis of OHS (according to Obesity (BMI ≥30 kg/m2) and Hypercapnic respiratory failure (PaCO2 ≥45 mmHg at hospital discharge) not secondary to other causes.
3. º - Hospitalized for an episode of acute-on-chronic hypercapnic respiratory failure, receiving hospital therapy with invasive or noninvasive ventilation, and just deemed stable for home discharge."
4. º.- No NIV or CPAP home therapy in the last 6 months\[\*\].
5. º.- Being able to tolerate and correctly execute a 15-minute test with automatic NIV (AVAPS-AE) and another 15-minute test with fixed CPAP treatments during wakefulness.
6. º.- Providing informed consent (dated and signed).

\[\*\] Patients who have objective evidence of minimal PAP therapy during the 6 months prior to hospital admission (i.e. average daily use of less than 2 hours of PAP therapy) can also be enrolled at the discretion of the investigators if they feel the patient is now more interested in being adherent to NIV therapy.

Inclusion criteria for the second phase of the study:

1º.- Included three months ago in the first phase of the study (followed by a washout period of 5 days).

Exclusion Criteria:

Exclusion criteria for the first phase of the study:

1. º.- With moderate or severe chronic obstructive pulmonary disease (FEV1\<70% of predicted when FEV1/FVC is below 70%).
2. º.- With neuromuscular disease, thoracic wall or metabolic disease that may cause diurnal hypercapnia.
3. º.- Inability to maintain a patent airway or adequately clear secretions.
4. º.- With bullous lung disease or with pneumothorax.
5. º.- With bypassed upper airway (i.e. endotracheal tube or tracheostomy).
6. º.- With anatomical abnormalities of the craniofacial structure leading to cerebral spinal fluid leaks, abnormalities of the cribriform plate, and/or pneumocephalus.
7. º.- At risk for aspiration of gastric contents.
8. º.- Diagnosed with acute sinusitis or otitis media.
9. º.- With active hemoptysis or epistaxis if presenting a risk of causing pulmonary aspiration of blood.
10. º.- With symptomatic hypotension.
11. º.- With clinical diagnosis of narcolepsy or restless leg syndrome.
12. º.- Psycho-physical incapacity to complete questionnaires.
13. º.- With diagnosis of chronic illness that might interfere the evaluation using quality of life questionnaires (neoplasia, severe chronic pain of any type, and any other severe chronic debilitating illness).
14. º.- Suffering other clinically relevant disease that, under the opinion of the investigator, might affect the evaluations of efficacy or safety.
15. º.- Participating simultaneously in other clinical study with intervention (or without intervention at the discretion of the investigator and with the consent of the Sponsor) or had participated in other clinical study with intervention within the last 30 days before the inclusion in this study. \[‡\]
16. º.- If for any reason (planned surgery \[including bariatric surgery\], trips of long duration, etc.) would not be able to receive the treatment and/or attend the follow-up visits of this study within the next three years and three months.
17. º.- Persons deprived of liberty by judicial or administrative decision, persons under psychiatric treatment and persons placed in a health or social institution for purposes other than those of this clinical study.
18. º.- Adults who are subject to a legal protection measure or who are unable to express their consent.

\[‡\] This prohibition shall be maintained for the duration of the patients' participation in the study. This is because, if patients received other treatments, it could be difficult to interpret the causality of the results obtained (whether beneficial or harmful effects) and the possible contraindications.

vi. Exclusion criteria for the second phase of the study:

1º.- With apnea hypopnea index (AHI) lower than 5 (absence or very mild obstructive sleep apnea).

Primary outcomes:
measure: Medium-term composite hospital resource utilization-mortality
timeFrame: 3 months
measure: Long-term composite hospital resource utilization-mortality
timeFrame: 3 years
Secondary outcomes:
measure: Hospital admissions
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: ICU admissions
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Emergency department visits
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: All-cause mortality
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Duration of hospital admissions
timeFrame: During 3 months and during 3 years for the first and second phase or sequential RCTs respectively
measure: Duration of ICU admissions
timeFrame: During 3 months and during 3 years for the first and second phase or sequential RCTs respectively
measure: Number of patients who change of the allocated arms
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Causes of change of the allocated treatment
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Clinical symptoms: lower extremity edema
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: Clinical symptoms: unrefreshing sleep
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: Clinical symptoms: morning fatigue
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Clinical symptoms: nocturia
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Clinical symptoms: headache
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Clinical symptoms: tiredness
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Clinical symptoms: morning confusion
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Clinical symptoms: dysnea
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Clinical symptoms: sleepiness
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Health related quality of life (HRQL): Functional Outcomes of Sleep Questionnaire-- FOSQ--
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: Health related quality of life (HRQL): European health-related quality of life questionnaire (EuroQol) EQ-5D-5L
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Health related quality of life (HRQL): Subjective state of illness on a visual analogical scale: Visual Analogical Well-being Scale -VAWS (Masa JF et al. Sleep Breath. 2011;15:549-59) (EuroQol) EQ-5D-5L
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Arterial blood gases (ABG): PaO2
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Arterial blood gases (ABG): PaCO2
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Arterial blood gases (ABG): Bicarbonate
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Arterial blood gases (ABG): pH
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Weight
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Standardized blood pressure measures
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: systemic hypertension
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: arrhythmia
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: nonfatal myocardial infarction
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: hospitalization for unstable angina
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: coronary percutaneous interventions
timeFrame: After 3 months and after 3 years for first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: nonfatal stroke or transient ischemic attack
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: heart failure episode
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Incidence of cardiovascular events: cardiovascular death
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Incidence of adverse event
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Cost-effectiveness analysis based on the primary outcome and quality adjusted life year (QALY)
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Number of oro-tracheal intubation
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
measure: Duration of tracheal intubation
timeFrame: During 3 months and during 3 years for the first and second phases or sequential RCTs respectively
Other outcomes:
measure: A composite outcome in adherent vs. non-adherent to PAP therapy subgroups
timeFrame: During 3 months for the first phase or RCT
measure: A composite outcome in adherent vs. non-adherent to PAP therapy subgroups
timeFrame: During 3 years for the second phase or RCT
measure: Subgroups according to whether hypercapnia was resolved or not
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: A composite outcome in subgroups with or without supplemental oxygen at baseline
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: A composite outcome in subgroups of hypercapnia severity at baseline
timeFrame: During 3 months and During 3 years for first and second phases or sequential RCTs respectively
measure: A composite outcome in subgroups of the apnea-hypopnea index severity at baseline
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: A composite outcome in subgroups with or without hypertension diagnosis at baseline
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: A composite outcome in subgroups with different home care providers
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
measure: Validity analysis of EQ 5D-5L test
timeFrame: During 3 months and during 3 years for first and second phases or sequential RCTs respectively
Locations:
Study officials:
affiliation: Servicio Extremeño de Salud
name: Juan F Masa, MD, Phd
role: PRINCIPAL_INVESTIGATOR
affiliation: Rush University Medical Center
name: Babak Mokhlesi, MD, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Storre JH, Seuthe B, Fiechter R, Milioglou S, Dreher M, Sorichter S, Windisch W. Average volume-assured pressure support in obesity hypoventilation: A randomized crossover trial. Chest. 2006 Sep;130(3):815-21. doi: 10.1378/chest.130.3.815.
citation: Masa JF, Rubio M, Findley LJ. Habitually sleepy drivers have a high frequency of automobile crashes associated with respiratory disorders during sleep. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1407-12. doi: 10.1164/ajrccm.162.4.9907019.
citation: Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med. 1999 Mar 18;340(11):847-51. doi: 10.1056/NEJM199903183401104.
citation: Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 Mar 19-25;365(9464):1046-53. doi: 10.1016/S0140-6736(05)71141-7.
citation: Kessler R, Chaouat A, Schinkewitch P, Faller M, Casel S, Krieger J, Weitzenblum E. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest. 2001 Aug;120(2):369-76. doi: 10.1378/chest.120.2.369.
citation: Masa JF, Corral J, Alonso ML, Ordax E, Troncoso MF, Gonzalez M, Lopez-Martinez S, Marin JM, Marti S, Diaz-Cambriles T, Chiner E, Aizpuru F, Egea C; Spanish Sleep Network. Efficacy of Different Treatment Alternatives for Obesity Hypoventilation Syndrome. Pickwick Study. Am J Respir Crit Care Med. 2015 Jul 1;192(1):86-95. doi: 10.1164/rccm.201410-1900OC.
citation: Castro-Anon O, Perez de Llano LA, De la Fuente Sanchez S, Golpe R, Mendez Marote L, Castro-Castro J, Gonzalez Quintela A. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. PLoS One. 2015 Feb 11;10(2):e0117808. doi: 10.1371/journal.pone.0117808. eCollection 2015.
citation: Basoglu OK, Tasbakan MS. Comparison of clinical characteristics in patients with obesity hypoventilation syndrome and obese obstructive sleep apnea syndrome: a case-control study. Clin Respir J. 2014 Apr;8(2):167-74. doi: 10.1111/crj.12054. Epub 2013 Nov 28.
citation: Priou P, Hamel JF, Person C, Meslier N, Racineux JL, Urban T, Gagnadoux F. Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest. 2010 Jul;138(1):84-90. doi: 10.1378/chest.09-2472. Epub 2010 Mar 26.
citation: Berg G, Delaive K, Manfreda J, Walld R, Kryger MH. The use of health-care resources in obesity-hypoventilation syndrome. Chest. 2001 Aug;120(2):377-83. doi: 10.1378/chest.120.2.377.
citation: Corral J, Mogollon MV, Sanchez-Quiroga MA, Gomez de Terreros J, Romero A, Caballero C, Teran-Santos J, Alonso-Alvarez ML, Gomez-Garcia T, Gonzalez M, Lopez-Martinez S, de Lucas P, Marin JM, Romero O, Diaz-Cambriles T, Chiner E, Egea C, Lang RM, Mokhlesi B, Masa JF; Spanish Sleep Network. Echocardiographic changes with non-invasive ventilation and CPAP in obesity hypoventilation syndrome. Thorax. 2018 Apr;73(4):361-368. doi: 10.1136/thoraxjnl-2017-210642. Epub 2017 Nov 16.
citation: Masa JF, Corral J, Romero A, Caballero C, Teran-Santos J, Alonso-Alvarez ML, Gomez-Garcia T, Gonzalez M, Lopez-Martin S, De Lucas P, Marin JM, Marti S, Diaz-Cambriles T, Chiner E, Merchan M, Egea C, Obeso A, Mokhlesi B; Spanish Sleep Network( *). Protective Cardiovascular Effect of Sleep Apnea Severity in Obesity Hypoventilation Syndrome. Chest. 2016 Jul;150(1):68-79. doi: 10.1016/j.chest.2016.02.647. Epub 2016 Feb 27.
citation: Weitzenblum E, Kessler R, Chaouat A. [Alveolar hypoventilation in the obese: the obesity-hypoventilation syndrome]. Rev Pneumol Clin. 2002 Apr;58(2):83-90. French.
citation: Chaouat A, Weitzenblum E, Krieger J, Sforza E, Hammad H, Oswald M, Kessler R. Prognostic value of lung function and pulmonary haemodynamics in OSA patients treated with CPAP. Eur Respir J. 1999 May;13(5):1091-6. doi: 10.1034/j.1399-3003.1999.13e25.x.
citation: Biring MS, Lewis MI, Liu JT, Mohsenifar Z. Pulmonary physiologic changes of morbid obesity. Am J Med Sci. 1999 Nov;318(5):293-7. doi: 10.1097/00000441-199911000-00002.
citation: Leech J, Onal E, Aronson R, Lopata M. Voluntary hyperventilation in obesity hypoventilation. Chest. 1991 Nov;100(5):1334-8. doi: 10.1378/chest.100.5.1334.
citation: Zwillich CW, Sutton FD, Pierson DJ, Greagh EM, Weil JV. Decreased hypoxic ventilatory drive in the obesity-hypoventilation syndrome. Am J Med. 1975 Sep;59(3):343-8. doi: 10.1016/0002-9343(75)90392-7.
citation: MacGregor MI, Block AJ, Ball WC Jr. Topics in clinical medicine: serious complications and sudden death in the Pickwickian syndrome. Johns Hopkins Med J. 1970 May;126(5):279-95. No abstract available.
citation: Miller A, Granada M. In-hospital mortality in the Pickwickian syndrome. Am J Med. 1974 Feb;56(2):144-50. doi: 10.1016/0002-9343(74)90591-9. No abstract available.
citation: Jennum P, Kjellberg J. Health, social and economical consequences of sleep-disordered breathing: a controlled national study. Thorax. 2011 Jul;66(7):560-6. doi: 10.1136/thx.2010.143958. Epub 2011 Jan 2.
citation: Olson AL, Zwillich C. The obesity hypoventilation syndrome. Am J Med. 2005 Sep;118(9):948-56. doi: 10.1016/j.amjmed.2005.03.042.
citation: Berger KI, Ayappa I, Chatr-Amontri B, Marfatia A, Sorkin IB, Rapoport DM, Goldring RM. Obesity hypoventilation syndrome as a spectrum of respiratory disturbances during sleep. Chest. 2001 Oct;120(4):1231-8. doi: 10.1378/chest.120.4.1231.
citation: Masa JF, Corral J, Caballero C, Barrot E, Teran-Santos J, Alonso-Alvarez ML, Gomez-Garcia T, Gonzalez M, Lopez-Martin S, De Lucas P, Marin JM, Marti S, Diaz-Cambriles T, Chiner E, Egea C, Miranda E, Mokhlesi B; Spanish Sleep Network; Garcia-Ledesma E, Sanchez-Quiroga MA, Ordax E, Gonzalez-Mangado N, Troncoso MF, Martinez-Martinez MA, Cantalejo O, Ojeda E, Carrizo SJ, Gallego B, Pallero M, Ramon MA, Diaz-de-Atauri J, Munoz-Mendez J, Senent C, Sancho-Chust JN, Ribas-Solis FJ, Romero A, Benitez JM, Sanchez-Gomez J, Golpe R, Santiago-Recuerda A, Gomez S, Bengoa M. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax. 2016 Oct;71(10):899-906. doi: 10.1136/thoraxjnl-2016-208501. Epub 2016 Jul 12.
citation: Masa JF, Mokhlesi B, Benitez I, Gomez de Terreros FJ, Sanchez-Quiroga MA, Romero A, Caballero-Eraso C, Teran-Santos J, Alonso-Alvarez ML, Troncoso MF, Gonzalez M, Lopez-Martin S, Marin JM, Marti S, Diaz-Cambriles T, Chiner E, Egea C, Barca J, Vazquez-Polo FJ, Negrin MA, Martel-Escobar M, Barbe F, Corral J; Spanish Sleep Network. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet. 2019 Apr 27;393(10182):1721-1732. doi: 10.1016/S0140-6736(18)32978-7. Epub 2019 Mar 29.
citation: Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respir Care. 2010 Oct;55(10):1347-62; discussion 1363-5.
citation: Lee WY, Mokhlesi B. Diagnosis and management of obesity hypoventilation syndrome in the ICU. Crit Care Clin. 2008 Jul;24(3):533-49, vii. doi: 10.1016/j.ccc.2008.02.003.
citation: Berry RB, Chediak A, Brown LK, Finder J, Gozal D, Iber C, Kushida CA, Morgenthaler T, Rowley JA, Davidson-Ward SL; NPPV Titration Task Force of the American Academy of Sleep Medicine. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med. 2010 Oct 15;6(5):491-509.
citation: Mokhlesi B, Masa JF, Brozek JL, Gurubhagavatula I, Murphy PB, Piper AJ, Tulaimat A, Afshar M, Balachandran JS, Dweik RA, Grunstein RR, Hart N, Kaw R, Lorenzi-Filho G, Pamidi S, Patel BK, Patil SP, Pepin JL, Soghier I, Tamae Kakazu M, Teodorescu M. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 Aug 1;200(3):e6-e24. doi: 10.1164/rccm.201905-1071ST.
citation: Carrillo A, Ferrer M, Gonzalez-Diaz G, Lopez-Martinez A, Llamas N, Alcazar M, Capilla L, Torres A. Noninvasive ventilation in acute hypercapnic respiratory failure caused by obesity hypoventilation syndrome and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Dec 15;186(12):1279-85. doi: 10.1164/rccm.201206-1101OC. Epub 2012 Oct 26.
citation: Howard ME, Piper AJ, Stevens B, Holland AE, Yee BJ, Dabscheck E, Mortimer D, Burge AT, Flunt D, Buchan C, Rautela L, Sheers N, Hillman D, Berlowitz DJ. A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome. Thorax. 2017 May;72(5):437-444. doi: 10.1136/thoraxjnl-2016-208559. Epub 2016 Nov 15.
citation: Murphy PB, Davidson C, Hind MD, Simonds A, Williams AJ, Hopkinson NS, Moxham J, Polkey M, Hart N. Volume targeted versus pressure support non-invasive ventilation in patients with super obesity and chronic respiratory failure: a randomised controlled trial. Thorax. 2012 Aug;67(8):727-34. doi: 10.1136/thoraxjnl-2011-201081. Epub 2012 Mar 1.
citation: Palm A, Midgren B, Janson C, Lindberg E. Gender differences in patients starting long-term home mechanical ventilation due to obesity hypoventilation syndrome. Respir Med. 2016 Jan;110:73-8. doi: 10.1016/j.rmed.2015.11.010. Epub 2015 Nov 26.
citation: Budweiser S, Riedl SG, Jorres RA, Heinemann F, Pfeifer M. Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. J Intern Med. 2007 Apr;261(4):375-83. doi: 10.1111/j.1365-2796.2007.01765.x.
citation: Borel JC, Burel B, Tamisier R, Dias-Domingos S, Baguet JP, Levy P, Pepin JL. Comorbidities and mortality in hypercapnic obese under domiciliary noninvasive ventilation. PLoS One. 2013;8(1):e52006. doi: 10.1371/journal.pone.0052006. Epub 2013 Jan 16.
citation: McArdle N, Rea C, King S, Maddison K, Ramanan D, Ketheeswaran S, Erikli L, Baker V, Armitstead J, Richards G, Singh B, Hillman D, Eastwood P. Treating Chronic Hypoventilation With Automatic Adjustable Versus Fixed EPAP Intelligent Volume-Assured Positive Airway Pressure Support (iVAPS): A Randomized Controlled Trial. Sleep. 2017 Oct 1;40(10). doi: 10.1093/sleep/zsx136.